Methotrexate
SIAL/M9929 - meets USP testing specifications
Synonym: Methotrexate hydrate; 4-
CAS Number: 133073-73-1
Empirical Formula (Hill Notation): C20H22N8O5 · xH2O
Molecular Weight: 454.44 (anhydrous basis)
MDL Number: MFCD00150847
Linear Formula: C20H22N8O5 · xH2O
Product Type: Chemical
agency | meets USP testing specifications |
USP/NF | |
form | powder |
InChI | 1S/C20H22N8O5.H2O/c1-28(9 |
InChI key | FPJYMUQSRFJSEW-ZOWNYOTGSA |
Quality Level | 200 ![]() |
SMILES string | [H]O[H].CN(Cc1cnc2nc(N)nc |
storage temp. | −20°C |
Application: | Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also effective in treatment of pyrimethamine-resistant Plasmodium vivax malaria parasites. |
Application: | Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also shows immunosuppressive effects in, e.g., rheumatoid arthritis. |
Biochem/physiol Actions: | Methotrexate is an allosteric inhibititor of dihydrofolate reductase (DHFR), the enzyme that catalyzes the conversion of dihydrofolate to tetrahydrofolate. Since tetrahydrolfolate is required for purine and pyrimidine synthesis, methotrexate treatment results in the inhibition of DNA and RNA synthesis. |
Packaging: | 25, 100, 500 mg in poly bottle |
Symbol | ![]() ![]() |
Signal word | Danger |
Hazard statements | H301 - H315 - H319 - H360FD |
Precautionary statements | P201 - P202 - P264 - P301 + P310 - P302 + P352 - P305 + P351 + P338 |
Hazard Codes | T |
Risk Statements | 61-25-36/38 |
Safety Statements | 53-26-36/37-45 |
RIDADR | UN 1544PSN1 6.1 / PGIII |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Storage Temp. | −20°C |
UNSPSC | 12352200 |